3160 – METABOLIC REWIRING IN AML-INITIATING CELLS CREATES A SELECTIVE DEPENDENCY ON BCAA METABOLISM

McKenzie Patrick,Zhimin Gu,Junhua Lyu,Hui Cao,Pranita Kaphle,Stephen Chung,Ralph DeBerardinis,Jian Xu

DOI: https://doi.org/10.1016/j.exphem.2022.07.216

IF: 3.249

2022-01-01

Experimental Hematology

Abstract:Increased expression of BCAT1, the first enzyme catalyzing branched-chain amino acids (BCAA) metabolism, is associated with poor survival in acute myeloid leukemia (AML). Prior studies of BCAT1 or BCAAs in cancer cell metabolism and phenotypes were based on in vitro or ex vivo cultured cells that do not fully recapitulate metabolism in an intact organism; therefore, the in vivo functional and mechanistic roles of BCAA metabolism in normal and malignant hematopoiesis remains unknown. To address this, we established conditional Bcat1 knockout (KO) and knock-in overexpression (OE) mouse models. We found that BCAT1 is dispensable for normal hematopoiesis, whereas BCAT1 OE increases hematopoietic stem cell frequency and function. BCAT1 expression is significantly increased in human primary AML samples containing FLT3 mutations but decreased in AML with MLL abnormalities, raising a fundamental question about how distinct oncogenic drivers create selective metabolic dependencies. Using retroviral and genetic murine leukemia models, we discovered that BCAT1 is required for leukemia initiation and maintenance of FLT3-ITD-driven AML in vivo, and BCAT1 OE synergizes with FLT3-ITD to promote leukemia transformation. In contrast, BCAT1 KO or OE had no effect on MLL-AF9-driven leukemia initiation or maintenance. By integrative analysis of metabolomic, transcriptomic, and metabolic flux profiles of AML-initiating cells with distinct oncogenic drivers, we aim to elucidate the underlying mechanisms responsible for onco-genotype-induced reprogramming of BCAA metabolism. Hence, using stringent genetic studies in preclinical models, our findings not only establish BCAT1 and BCAA as a metabolic dependency of AML-initiating cells in vivo, but also uncover new insights into onco-genotype-induced metabolic rewiring as a selective and targetable vulnerability. Increased expression of BCAT1, the first enzyme catalyzing branched-chain amino acids (BCAA) metabolism, is associated with poor survival in acute myeloid leukemia (AML). Prior studies of BCAT1 or BCAAs in cancer cell metabolism and phenotypes were based on in vitro or ex vivo cultured cells that do not fully recapitulate metabolism in an intact organism; therefore, the in vivo functional and mechanistic roles of BCAA metabolism in normal and malignant hematopoiesis remains unknown. To address this, we established conditional Bcat1 knockout (KO) and knock-in overexpression (OE) mouse models. We found that BCAT1 is dispensable for normal hematopoiesis, whereas BCAT1 OE increases hematopoietic stem cell frequency and function. BCAT1 expression is significantly increased in human primary AML samples containing FLT3 mutations but decreased in AML with MLL abnormalities, raising a fundamental question about how distinct oncogenic drivers create selective metabolic dependencies. Using retroviral and genetic murine leukemia models, we discovered that BCAT1 is required for leukemia initiation and maintenance of FLT3-ITD-driven AML in vivo, and BCAT1 OE synergizes with FLT3-ITD to promote leukemia transformation. In contrast, BCAT1 KO or OE had no effect on MLL-AF9-driven leukemia initiation or maintenance. By integrative analysis of metabolomic, transcriptomic, and metabolic flux profiles of AML-initiating cells with distinct oncogenic drivers, we aim to elucidate the underlying mechanisms responsible for onco-genotype-induced reprogramming of BCAA metabolism. Hence, using stringent genetic studies in preclinical models, our findings not only establish BCAT1 and BCAA as a metabolic dependency of AML-initiating cells in vivo, but also uncover new insights into onco-genotype-induced metabolic rewiring as a selective and targetable vulnerability.